These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
474 related articles for article (PubMed ID: 18281662)
1. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662 [TBL] [Abstract][Full Text] [Related]
2. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review. Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Mutch DG; Orlando M; Goss T; Teneriello MG; Gordon AN; McMeekin SD; Wang Y; Scribner DR; Marciniack M; Naumann RW; Secord AA J Clin Oncol; 2007 Jul; 25(19):2811-8. PubMed ID: 17602086 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Ferrandina G; Paris I; Ludovisi M; D'Agostino G; Testa A; Lorusso D; Zanghi M; Pisconti S; Pezzella G; Adamo V; Breda E; Scambia G Gynecol Oncol; 2005 Aug; 98(2):267-73. PubMed ID: 15975643 [TBL] [Abstract][Full Text] [Related]
6. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083 [TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695 [TBL] [Abstract][Full Text] [Related]
8. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Tas F; Guney N; Derin D; Aydiner A; Topuz E Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961 [TBL] [Abstract][Full Text] [Related]
10. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Ferrandina G; Ludovisi M; Corrado G; Carone V; Petrillo M; Scambia G Gynecol Oncol; 2008 May; 109(2):187-93. PubMed ID: 18343487 [TBL] [Abstract][Full Text] [Related]
11. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J; Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267 [TBL] [Abstract][Full Text] [Related]
13. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380 [TBL] [Abstract][Full Text] [Related]
14. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445 [TBL] [Abstract][Full Text] [Related]
15. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221 [TBL] [Abstract][Full Text] [Related]
17. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470 [TBL] [Abstract][Full Text] [Related]
18. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Harbeck N; Saupe S; Jäger E; Schmidt M; Kreienberg R; Müller L; Otremba BJ; Waldenmaier D; Dorn J; Warm M; Scholz M; Untch M; de Wit M; Barinoff J; Lück HJ; Harter P; Augustin D; Harnett P; Beckmann MW; Al-Batran SE; Breast Cancer Res Treat; 2017 Jan; 161(1):63-72. PubMed ID: 27798749 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine. Takahashi Y; Takei Y; Machida S; Taneichi A; Takahashi S; Yoshiba T; Koyanagi T; Tamura K; Saga Y; Fujiwara H J Obstet Gynaecol Res; 2021 Feb; 47(2):551-559. PubMed ID: 33145906 [TBL] [Abstract][Full Text] [Related]
20. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]